Stock INDSWFTLAB IND-SWIFT LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Ind-Swift Laboratories Limited

Equities

INDSWFTLAB

INE915B01019

Market Closed - NSE India S.E.
Other stock markets
 07:43:48 2024-04-19 am EDT 		5-day change 1st Jan Change
118.6 INR +1.76% Intraday chart for Ind-Swift Laboratories Limited -5.91% +14.53%
Apr. 19 Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai MT
Mar. 18 Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai
MT
Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer
CI
Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer
CI
Ind-Swift Laboratories Limited Redeems in Full, the 4245 Rated, Listed, Secured, 10% Coupon, Redeemable, Non-Convertible Debenture
CI
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited and Essix Biosciences Limited.
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
CARE Keeps BB Rating on Ind-Swift Laboratories' Long-term Financing; Rating Under Watch Developing
MT
Ind-Swift Laboratories Limited Collaborates with The Council of Scientific and Industrial Research
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023
CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited.
CI
IndiaRF to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 1,650 Crores
AQ
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories
MT
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 million
RE
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
CI
RN Chemicals & Pharmaceutical Private Limited acquired Halcyon life Sciences Private Limited from Ind-Swift Laboratories Limited for INR 5 million.
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
CI
Ex-dividend day for final dividend
FA
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INDSWFTLAB Stock
  4. News Ind-Swift Laboratories Limited